Eptinezumab Brand Name– Vyepti
What is Eptinezumab
Eptinezumab is an injectable calcitonin gene-related peptide (CGRP) receptor antagonist indicated for migraine prophylaxis in adults.
In a clinical trial of patients with episodic migraine, monthly migraine days were significantly reduced by 3.9 to 4.3 days from baseline at 3 months in eptinezumab-treated patients in comparison to 3.2 days for placebo.
At month 3, eptinezumab-treated chronic migraine patients experienced a significant 7.7 to 8.2-day reduction in monthly migraine days from baseline in comparison to 5.6 days for placebo.
A 50% or greater reduction in monthly migraine days was achieved by 49.8% to 56.3% of episodic migraineurs and 57.6% to 61.4% of chronic migraineurs who were treated with eptinezumab compared to 37.4% of episodic migraineurs and 39.3% of chronic migraineurs given placebo
Indications
- migraine prophylaxis
Guideline indications for initiating migraine prophylaxis with monoclonal antibodies to calcitonin gene-related peptide (CGRP) or its receptor:
- Migraine with or without aura (4 to 7 monthly headache days) and inability to tolerate or inadequate response to a 6-week trial of at least 2 evidence-based preventative treatments and at least moderate disability defined by Migraine Disability Assessment Score (MIDAS) more than 11 or Headache Impact Test Score (HIT-6) more than 50
- Migraine with or without aura (8 to 14 monthly headache days) and inability to tolerate or inadequate response to a 6-week trial of at least 2 evidence-based preventative treatments
- Chronic migraine and inability to tolerate or inadequate response to a 6-week trial of at least 2 evidence-based preventative treatments or inability to tolerate or inadequate response to a minimum of 2 quarterly injections (6 months) of onabotulinumtoxinA
Side Effects
- angioedema
- antibody formation
- flushing
- pharyngitis
- rash
- urticaria
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- pregnancy
Interactions
There are no drug interactions associated with Eptinezumab products.